Related coverage linked through entity extraction aliases.
Jul 28, 2026
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
May 26, 2026
Iovance's Amtagvi achieved a 44% confirmed objective response rate and 73% disease control in an advanced melanoma study. Goldman Sachs raised its price target to $2, maintaining a Sell rating.
May 28, 2026
The Trump administration barred NIAID officials from WHO meetings, reclaimed $600M from four states, and faced a Senate report showing drug prices rising despite deals. New drugs average $353K a year.
Mar 31, 2026
Ultragenyx received FDA clearance for UX016 in GNE myopathy, with a Phase 1/2 study planned for 2026. Soligenix's confirmatory HyBryte trial for CTCL has 66 of 80 patients enrolled, and an interim analysis is expected in early 2026.
Aug 09, 2026
The FDA approved Moderna's mFlusiva, the first mRNA-based flu vaccine, for adults 50 and older. Full approval covers ages 50-64; accelerated approval covers 65+. Moderna expects availability later this year, pending CDC recommendation.
Jul 22, 2026
Recent Rethinking Clinical Trials Grand Rounds sessions covered the COMPARE-Pediatric IBD study, a hypertension self-management texting intervention for Black Veterans, and the upcoming Pediatric Trials Network presentation.
Jul 29, 2026
Phase 3 PROTEUS: perioperative apalutamide plus ADT met both dual primary endpoints in high-risk localized prostate cancer, raising pCR/MRD rates to 8.9% vs 1.0% and cutting metastasis or death risk by 20%.
Aug 08, 2026
AstraZeneca is expanding in China with a $200m upfront COPD drug license from Sino Biopharmaceutical, a $1.5bn licensing deal for Dizal's Zegfrovy, and a $15bn manufacturing and R&D investment. The deals add revenue-generating assets to its respiratory and oncology portfolios.
Aug 08, 2026
A WashU Medicine study found Moderna's investigational mRNA flu vaccine could reduce hospitalizations and deaths, offering longer protection than current shots. If FDA-approved, it would be the first mRNA flu vaccine, with a decision possible by early August.
Jul 23, 2026
Transcripta Bio raised $24M backed by Mayo Clinic and Omnimed for AI-driven neurological and neuromuscular therapies. The funds will support IND-enabling studies and clinical preparation for ASD and FSHD programs.
Aug 08, 2026
TMates Weightloss Semaglutide is a compounded semaglutide telehealth program dispensed by U.S. pharmacies. It offers tailored dosing, a 30-day money-back guarantee, and support for appetite control and weight maintenance.
Apr 29, 2026
Global biologics market projected to grow to USD 1.28 trillion by 2035; Japan cell and gene therapy market to reach USD 2.15 billion by 2034; Japan biologic drug lifecycle management market to hit USD 9.69 billion by 2033.
Jul 12, 2026
WHO has launched the PARTNERS clinical trial testing MBP134 and remdesivir for Bundibugyo virus disease in the DRC. Advisers recommend limiting all candidate Ebola drugs to clinical trials. The outbreak has caused 1,792 confirmed cases and 625 deaths as of July 9.
Jul 01, 2026
New reports project clinical trials markets to grow sharply: decentralized trials to $38.3B by 2035, omics-based trials to $47.78B by 2030, women's trials to $22.3B by 2036, and software to $34.15B by 2035.
Aug 04, 2026
Semaglutide may lower risks of adult-onset seizures and alcohol-related hospitalizations, new studies find. Brazil approved five semaglutide injectables, and a commentary updates obesity care with GLP-1 drugs.
May 23, 2026
Pfizer reported positive topline PFS results for encorafenib plus cetuximab and FOLFIRI in BRAF V600E-mutant mCRC from BREAKWATER cohort 3. The regimen showed significant PFS improvement and clinically meaningful OS benefit, with no new safety signals.
Aug 06, 2026
FDA approved Orzeyful (oveporexton), the first drug to target the underlying loss of orexin signaling in narcolepsy type 1. In two 12-week trials, the twice-daily tablet improved wakefulness and reduced cataplexy versus placebo.
Jul 10, 2026
Merck Animal Health received FDA conditional approval for Exzolt Cattle-CA1 to prevent and treat New World screwworm in beef cattle. The company hosted a San Antonio symposium urging industrywide collaboration and preparedness.
Jul 08, 2026
A randomized trial showed Cepheid's Xpert Xpress MVP point-of-care test improved appropriate treatment for vaginitis within 24 hours. Other modeling found treating male partners of women with bacterial vaginosis reduced recurrence and was cost-saving.
Jul 31, 2026
Benchmark studies show general-purpose LLMs like GPT-5.2, Gemini 3.1 Pro, and Claude Opus 4.6 outperform FDA-cleared clinical AI tools and physicians on diagnostic reasoning tasks. Domain-adapted LLMs also beat larger generic models on clinical research tasks, while agentic systems show only modest gains. Regulatory clearance pathways have not yet addressed comparative performance.
